Cargando…
Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosis
BACKGROUND: Pulmonary fibrosis is an untreatable, fatal disease characterized by excess deposition of extracellular matrix and inflammation. Although the etiology of pulmonary fibrosis is unknown, recent studies have implicated dysregulated immune responses and wound healing. Since n-3 polyunsaturat...
Autores principales: | Zhao, Hongyun, Chan-Li, Yee, Collins, Samuel L, Zhang, Yuan, Hallowell, Robert W, Mitzner, Wayne, Horton, Maureen R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998951/ https://www.ncbi.nlm.nih.gov/pubmed/24742272 http://dx.doi.org/10.1186/1471-2466-14-64 |
Ejemplares similares
-
Lovastatin Inhibits Low Molecular Weight Hyaluronan Induced Chemokine Expression via LFA-1 and Decreases Bleomycin-Induced Pulmonary Fibrosis
por: Hamblin, Mark J., et al.
Publicado: (2014) -
Pulmonary Vaccination as a Novel Treatment for Lung Fibrosis
por: Collins, Samuel L., et al.
Publicado: (2012) -
A mouse model of chronic idiopathic pulmonary fibrosis
por: Limjunyawong, Nathachit, et al.
Publicado: (2014) -
Transgenically-expressed secretoglobin 3A2 accelerates resolution of bleomycin-induced pulmonary fibrosis in mice
por: Cai, Yan, et al.
Publicado: (2015) -
Immune Mechanisms of Pulmonary Fibrosis with Bleomycin
por: Ishida, Yuko, et al.
Publicado: (2023)